Trial · NCT01263925
Results by group56
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 56
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline | Alprostadil | 2.60 | Standard Deviation 12.22 | meter/meter | |
| Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline | Pentoxifylline | 1.98 | Standard Deviation 3.61 | meter/meter | |
| Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings at Baseline | Alprostadil | 2.27 | Standard Deviation 3.00 | meter/meter | |
| Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings at Baseline | Pentoxifylline | 2.36 | Standard Deviation 2.69 | meter/meter | |
| Ratio of Pain-free Walking Distance After Period 1 in Comparison With the Findings at Baseline | Alprostadil | 1.58 | Standard Deviation 1.92 | meter/meter | |
| Ratio of Pain-free Walking Distance After Period 1 in Comparison With the Findings at Baseline | Pentoxifylline | 1.58 | Standard Deviation 2.59 | meter/meter | |
| Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings After Period 1 | Alprostadil | 1.25 | Standard Deviation 0.64 | meter/meter | |
| Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings After Period 1 | Pentoxifylline | 1.24 | Standard Deviation 0.50 | meter/meter | |
| Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 1 | Alprostadil | 1.54 | Standard Deviation 1.53 | meter/meter | |
| Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 1 | Pentoxifylline | 1.57 | Standard Deviation 1.10 | meter/meter | |
| Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 2 | Alprostadil | 1.26 | Standard Deviation 0.85 | meter/meter | |
| Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 2 | Pentoxifylline | 1.28 | Standard Deviation 0.74 | meter/meter | |
| Ratio of Maximum Walking Distance After Period 1 in Comparison With the Findings at Baseline | Alprostadil | 1.39 | Standard Deviation 0.53 | meter/meter | |
| Ratio of Maximum Walking Distance After Period 1 in Comparison With the Findings at Baseline | Pentoxifylline | 1.43 | Standard Deviation 1.34 | meter/meter | |
| Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings at Baseline | Alprostadil | 1.64 | Standard Deviation 0.86 | meter/meter | |
| Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings at Baseline | Pentoxifylline | 1.76 | Standard Deviation 1.78 | meter/meter | |
| Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings After Period 1 | Alprostadil | 1.20 | Standard Deviation 0.50 | meter/meter | |
| Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings After Period 1 | Pentoxifylline | 1.21 | Standard Deviation 0.41 | meter/meter | |
| Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings at Baseline | Alprostadil | 1.89 | Standard Deviation 1.40 | meter/meter | |
| Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings at Baseline | Pentoxifylline | 1.99 | Standard Deviation 1.61 | meter/meter |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01263925/results